Related Experiment Video

Updated: May 2, 2026

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

7.9K

Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies

Jorge J Castillo1, Meera Iyengar2, Benjamin Kuritzky2

  • 1Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.

Oncotargets and Therapy
|March 5, 2014
PubMed

Insights

Targeted therapies, like phosphatidylinositol-3-kinase (PI3K) inhibitors, are revolutionizing cancer treatment. This review details PI3K

Area of Science:

  • Oncology and Hematology
  • Molecular Biology
  • Pharmacology

Background:

  • Biological targeted therapies have transformed cancer care, particularly for hematologic malignancies.
  • The phosphatidylinositol-3-kinase (PI3K) pathway is implicated in the development and survival of blood cancers.
  • Leukemia, lymphoma, and myeloma are key hematologic malignancies where PI3K signaling is crucial.

Purpose of the Study:

  • To elucidate the current understanding of the PI3K pathway and its various isoforms.
  • To review preclinical and clinical research on PI3K inhibitors.
  • To highlight advancements in treating hematologic malignancies using PI3K-targeted agents.

Main Methods:

  • Literature review of preclinical studies on PI3K inhibitors.
  • Analysis of clinical trial data for PI3K inhibitors in hematologic cancers.
  • Synthesis of current knowledge on PI3K pathway biology.

Main Results:

  • The PI3K pathway is a significant factor in the pathogenesis of hematologic malignancies.
  • PI3K inhibitors have shown promise in preclinical models and early clinical trials.
  • Specific PI3K isoforms are being targeted for improved therapeutic efficacy.

Conclusions:

  • PI3K inhibitors represent a promising class of targeted therapies for hematologic malignancies.
  • Further research is needed to optimize PI3K inhibitor treatment strategies.
  • Targeting the PI3K pathway offers a novel approach to managing leukemia, lymphoma, and myeloma.
Keywords:
inhibitorsleukemialymphomamyelomaphosphatidylinositol-3-kinase pathway

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.5K